JP2014513143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513143A5 JP2014513143A5 JP2014509721A JP2014509721A JP2014513143A5 JP 2014513143 A5 JP2014513143 A5 JP 2014513143A5 JP 2014509721 A JP2014509721 A JP 2014509721A JP 2014509721 A JP2014509721 A JP 2014509721A JP 2014513143 A5 JP2014513143 A5 JP 2014513143A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- pharmaceutical composition
- benzoate
- pharmaceutically acceptable
- linagliptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 5
- 229960004034 sitagliptin Drugs 0.000 claims description 4
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 8
- 229960002397 linagliptin Drugs 0.000 claims 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 239000013078 crystal Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229920000298 Cellophane Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 239000004793 Polystyrene Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000002329 infrared spectrum Methods 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- -1 polyethylene vinyl acetate Polymers 0.000 claims 1
- 229920002223 polystyrene Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11165597.3 | 2011-05-10 | ||
| EP11165597 | 2011-05-10 | ||
| PCT/EP2012/058556 WO2012152837A1 (en) | 2011-05-10 | 2012-05-09 | Polymorph of linagliptin benzoate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513143A JP2014513143A (ja) | 2014-05-29 |
| JP2014513143A5 true JP2014513143A5 (https=) | 2016-06-30 |
| JP6028016B2 JP6028016B2 (ja) | 2016-11-16 |
Family
ID=44227877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509721A Expired - Fee Related JP6028016B2 (ja) | 2011-05-10 | 2012-05-09 | リナグリプチンベンゾエートの多形体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8785455B2 (https=) |
| EP (1) | EP2707368B1 (https=) |
| JP (1) | JP6028016B2 (https=) |
| CN (1) | CN103596954B (https=) |
| AU (1) | AU2012252380B2 (https=) |
| CA (1) | CA2835332C (https=) |
| EA (1) | EA023330B1 (https=) |
| SI (1) | SI2707368T1 (https=) |
| WO (1) | WO2012152837A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN105712995B (zh) * | 2014-12-05 | 2017-11-03 | 浙江京新药业股份有限公司 | 一种利格列汀的纯化方法 |
| KR102442536B1 (ko) * | 2015-09-17 | 2022-09-13 | 한미정밀화학주식회사 | 리나글립틴 결정형 및 이의 제조방법 |
| AU2016335082A1 (en) | 2015-10-09 | 2018-04-12 | Hexal Ag | Pharmaceutical composition containing 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| CN106543180B (zh) * | 2016-10-28 | 2018-03-30 | 南京正大天晴制药有限公司 | 苯甲酸利格列汀晶型及其制备方法 |
| US20210313015A1 (en) * | 2018-08-21 | 2021-10-07 | Towa Pharmaceutical Co., Ltd. | Specifically-shaped crystal of compound and method for producing same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1532149B9 (de) | 2002-08-21 | 2011-04-20 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel |
| DE102004054054A1 (de) * | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| JP2012512848A (ja) * | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| US8835472B2 (en) * | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
-
2012
- 2012-05-09 CA CA2835332A patent/CA2835332C/en active Active
- 2012-05-09 AU AU2012252380A patent/AU2012252380B2/en not_active Ceased
- 2012-05-09 JP JP2014509721A patent/JP6028016B2/ja not_active Expired - Fee Related
- 2012-05-09 EP EP12721484.9A patent/EP2707368B1/en not_active Not-in-force
- 2012-05-09 EA EA201301240A patent/EA023330B1/ru not_active IP Right Cessation
- 2012-05-09 CN CN201280028478.4A patent/CN103596954B/zh not_active Expired - Fee Related
- 2012-05-09 WO PCT/EP2012/058556 patent/WO2012152837A1/en not_active Ceased
- 2012-05-09 SI SI201230481T patent/SI2707368T1/sl unknown
- 2012-05-09 US US14/115,880 patent/US8785455B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513143A5 (https=) | ||
| JP6028016B2 (ja) | リナグリプチンベンゾエートの多形体 | |
| TWI400073B (zh) | 穩定之拉癸利莫（ｌａｑｕｉｎｉｍｏｄ）製劑 | |
| Ambrogi et al. | Use of SBA-15 for furosemide oral delivery enhancement | |
| JP6533317B2 (ja) | アナグリプチン含有固形製剤 | |
| JP2014524442A5 (https=) | ||
| JP2011509919A5 (https=) | ||
| JP2014005302A5 (https=) | ||
| RS67620B1 (sr) | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida | |
| JP2016523846A5 (https=) | ||
| CN102164585B (zh) | 含有氨氯地平和比索洛尔的组合物 | |
| JP6653116B2 (ja) | オルメサルタンのプロドラッグ製剤 | |
| JP2024033014A (ja) | 医薬組成物 | |
| JP2024033015A (ja) | 医薬品 | |
| RS60417B1 (sr) | Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode | |
| JP6215238B2 (ja) | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 | |
| JP7093752B2 (ja) | モンテルカストナトリウム製剤 | |
| JP2015509941A5 (https=) | ||
| WO2016097030A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide | |
| JP2014527506A5 (https=) | ||
| US9481652B2 (en) | Packaged product of solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or salt thereof, or hydrate thereof | |
| JP2020121776A (ja) | エソメプラゾール製剤の乾燥剤包装体 | |
| KR20140110921A (ko) | 포어가 거의 없는 무수 탄산나트륨 | |
| JP2012046484A5 (https=) | ||
| WO2013093751A1 (en) | Packaging for linezolid |